OBJECTIVE: To examine potential interactions between abdominal obesity, endocrine, metabolic and hemodynamic perturbations. SUBJECTS: A subgroup of 284 men from a population sample of 1040 at the age of 51 y. MEASUREMENTS: Anthropometric measurements included body mass index (BMI, kgam 2 ), waistahip circumference ratio (WHR) and abdominal sagittal diameter (D). Endocrine measurements were a modi®ed, low dose (0.5 mg) dexamethasone suppression test (Dex), testosterone (T) and insulin-like growth factor I (IGF-I). Overnight fasting values of blood glucose, serum insulin, triglycerides, total, low and high density lipoprotein cholesterol, as well as resting heart rate and blood pressure were also determined. RESULTS: Arbitrary subdivisions of the men were performed to obtain subgroups of low T and IGF-I values (lowest decile, borderlines 13.13 nmolal and 128.80 m mgal, respectively) and normal or blunted Dex. Signi®cant relationships with BMI, WHR or D, and abnormal metabolic and hemodynamic factors, usually with the exception of total and low density lipoprotein cholesterol, were then found in subgroups with different endocrine pro®les. These included men with a blunted Dex test with low T or IGF-I values, as well as men with a normal Dex test and low or normal T or IGF-I values. In addition, a group with isolated low Dex suppression, as well as another group without endocrine abnormalities, showed such relationships. These ®ndings suggest that, in men, obesity factors are associated with metabolic and hemodynamic complications with or without the presence of perturbations of hypothalamic-pituitaryadrenal axis (HPA) regulation or low T or growth hormone secretion. In order to generate hypotheses concerning the nature of the impact of the endocrine perturbations in abdominal obesity and its metabolic complications, path analyses were performed, testing different models. These models included the endocrine measurements (Dex test, T and IGF-I), the WHR and D (representing abdominal distribution of fat), BMI (representing obesity), as well as insulin and triglyceride values (representing metabolic perturbations). The results showed a satisfactory ®t (goodness-of-®t index: 0.945 ± 1.0) for the path diagrams: Dex ? TaIGF-I ? WHR or D ? insulin ? triglycerides with additional direct input of blunted Dex on insulin values (see Figure 1) . With BMI as determinant, essentially the same results were found with the addition of a direct pathway between Dex and BMI as well as between IGF-I-T and insulin (Figure 2 ). There was no evidence for pathways where WHR or BMI determined endocrine variables. CONCLUSIONS: The results suggest that abdominal obesity with or without endocrine abnormalities exerts a major impact on abnormalities in metabolic and hemodynamic variables. Abdominal obesity seems to be dependent on endocrine abnormalities, which in turn show direct or indirect relationships to the metabolic and circulatory variables, including a direct pathway between HPA-axis perturbations and accumulation of total body fat as indicated by the BMI. It is therefore suggested that endocrine perturbations are followed by obesity and by storage of an elevated proportion of fat in visceral depots, followed by metabolic and hemodynamic abnormalities. This is statistical evidence which is supported by evidence of mechanistic links in previous studies, suggesting the possibility of causal relationships. The results also indicate subgroups of abdominal obesity and its associated metabolic and hemodynamic abnormalities, which might be due to the input of different pathogenetic factors.
Introduction
Abdominal obesity is associated statistically with multiple endocrine abnormalities, including perturbations of the hypothalamic-pituitary-adrenal axis (HPA) regulation, 1,2 a relative hypogonadism in men, 3, 4 and hyperandrogenicity in women. 5 Further-more, visceral fat content is negatively related to insulin-like growth factor I (IGF-I), 6 an indicator of growth hormone (GH) secretion, 7 and followed by a few, small GH secretory peaks. 8 The most prominent endocrine abnormality associated with visceral obesity is, however, hyperinsulinaemia. 9, 10 We recently found that men with abdominal obesity often display a blunted inhibition of cortisol secretion by a low dose of Dexamethasone, 11 frequently associated with traits of anxiety and depression. 12 Furthermore, these men with abdominal obesity were characterised by low concentrations of both total testosterone (T) and IGF-I. 12 There is evidence that an elevated activity of the HPA axis may restrain both the pituitary gonadal and somatotropin axes. 13, 14 However, the results of studies of the men also indicated that there might be subjects with abdominal obesity without HPA-axis involvement. Primary de®-ciencies of sex steroid and growth hormone, not secondary to hyperactivity of the HPA axis, might be involved. In a recent study, simultaneous measurements of T and luteinizing hormone concentrations suggested that hypogonadism in abdominally obese men might be of both peripheral or testicular (primary) and central (secondary) origin. 15 Substitution with both T and GH is followed by reduction of central fat masses, as well as improvements in disturbances of carbohydrate and lipid metabolism. 16, 17 Taken together, these results suggest several possibilities of hormonal interactions in abdominal obesity. Perturbations of the regulation of the HPA axis seem to be frequent phenomena, but may not always be present. Similarly, low T and GH secretions may or may not be involved, and might be secondary to the HPA-axis abnormality 13 or originating from other primary causes. Since these endocrine perturbations might be involved in the pathogenesis of abdominal distribution of body fat 18 and its associated metabolic abnormalities, 19 we found it of interest to attempt to isolate subgroups with different endocrine pro®les, and to analyse the statistically associated metabolic and circulatory problems. Furthermore, abdominal obesity without endocrine abnormalities could be isolated and analysed similarly. This was performed in a group of middle-aged men where tertiles of body mass index (BMI), waistahip circumference ratio (WHR) and abdominal sagittal diameter (D) were arbitrarily used to obtain subgroups. Moreover, the lowest deciles of T and IGF-I were analysed separately as groups of relative T and GH de®ciency. Dexamethasone inhibition of cortisol secretion was used to de®ne HPA-axis activity. In this way subgroups were arbitrarily de®ned with or without obesity (BMI), abdominal fat distribution (WHR and D), relative T and GH de®ciency in relation to HPAaxis activity, as well as a subgroup without endocrine abnormalities. The relationships to metabolic and blood pressure (BP) variables were analysed in these subgroups. Furthermore, statistical path-analyses were performed in an attempt to generate hypotheses for Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp potential causal relationships between obesity, endocrine and metabolic factors.
The results suggest that there are subgroups of abdominal obesity with different endocrine pro®les and that the statistical origin of metabolic perturbations, as analysed in path-analytic models, might be found in any of these subgroups.
Subjects and methods

Study population
During 1992, a cohort of men (n 1302) were recruited from the National Population Register of Go Èteborg, Sweden. The target population comprised all men born during the ®rst six months of 1944 and living in Go Èteborg. A questionnaire was sent out to those who were selected, 20, 21 1040 men responded, resulting in a participation rate of 79.9%. Based on the self-reported WHR, three subgroups were selected as follows: 150 with the lowest ( 0.885), 150 with the highest (!1.01) and 150 around the arithmetic mean (0.94 ± 0.96) of WHR were de®ned. They were then invited to a health examination during 1995; 284 (63.1%) volunteered to participate. No men were excluded.
The study was approved by the Ethical Committee of the Medical Faculty of the University of Go Èteborg, and by the Swedish Data Inspection Board.
Examinations
All examinations were performed in the morning after an overnight fast and accomplished by the same research nurses and technicians.
Body weight was measured to the nearest 0.1 kg, with participants dressed in underwear, and the height was measured to the nearest cm. The body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kgam 2 ). The waist circumference was measured midway between the lower rib and the iliac crest, and the hip circumference at the level of the great trochanters. 22 The WHR was calculated as the ratio between the waist and hip circumferences. The abdominal sagittal diameter (D, cm) was determined as the distance between the examination table and the highest point of the abdomen in the recumbent position, and is a close approximation of visceral fat mass. 23 Salivary cortisol 24 was determined by radioimmunoassay (RIA, Orion Diagnostica, Turku, Finland). A sampling device called Salivette 1 (Sarstedt Inc., Rommelsdorf, Germany) was used to measure salivary cortisol levels. The Salivette 1 consists of a small cotton swab inside a standard centrifugation tube. 25 The participants were given three Salivettes 1 and one tablet of Dexamethasone (Decadron 1 , MSD Inc., Sweden) of 0.5 mg. They were asked to chew the cotton swab in the morning (08.00 ± 09.00 h) for 45 ± 60 s on two consecutive days. At 22.00 h on the second day, the Dexamethasone tablet was taken, and the following morning the salivary sampling was repeated. The participants were given careful verbal and written instructions. The decrease in salivary cortisol level after Dexamethasone administration was calculated as the mean of non-inhibited cortisol level minus the cortisol level after Dexamethasone intake.
Serum total T was determined by a non-extracting method, where T bound to bovine serum albumin at C-19 (Testosterone-19-Carboxymethylether-BSA) was used as the antigen (Testosterone 125 I RIA, ICN Biomedicals Inc., Costa Measa, USA). IGF-I was determined by hydrochloric acid-ethanol (12.5% 2N HCLa87.5% ETOH) extraction RIA (Nichols Institute Diagnostics, San Juan Capistrano, USA). Insulin was measured by RIA (Pharmacia Insulin RIA 100, Kabi Pharmacia Diagnostics, Uppsala, Sweden). Glucose was determined by a commercially available enzymatic method 26 and serum lipids as described by Wiklund et al.
27
Two BP measurements were taken, with the participants sitting, using a random-zero mercury sphygmomanometer on the right arm. 28 The BP was measured after ®ve minutes rest, with ®ve minutes interval between measurements and before blood samples were taken. Heart rate (HR) was recorded simultaneously. The individual mean systolic and diastolic BPS were calculated as the mean of the two measurements.
Statistical analysis
All data analyses were performed utilising SAS for Windows, release 6.12 (SAS Institute, Cary, NC). Two-tailed test was used throughout, and a P`0.05 was considered to be signi®cant. Standard methods were used to calculate the descriptive statistics. For relationship between pairs of variables, Spearman's rank-correlation coef®cient is given. 29 T and IGF-I were arranged into ten equal ordered groups for every 10th percentile of their frequencies. Based on this strati®cation, we de®ned the bottom 10th percentile for each hormone (that is, T 13.13 nmolal and IGF-I 128.80 mgal) and the upper 90% as a`comparative population'. Dexamethasone suppression was used to de®ne HPA axis status. Since normal values are not available for this measurement, the results were subjected to a statistical weighting procedure. Direct weighting emphasised ef®cient inhibition, while inverted values were used to de®ne poor inhibition. For convenience, these results were labelled`adequate' and`blunted' dexamethasone suppression, respectively.
The potential causal relationship between endocrine measurements, body fat distribution and metabolism, was evaluated by path-analytic models; 30, 31 an extension of multiple linear regression, that provides Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp estimates of the signi®cance of hypothesised causal connections between sets of variables. 30, 31 Test to prove that the proposed model ®ts the data was performed with Chi-square (w 2 ) statistics. In addition, Jo Èreskogs goodness-of-®t index (GFI) and GFI adjusted for degrees of freedom (AGFI) were calculated as concomitant measurements of overall ®t. 30 The GFI and AGFI range between zero and one, where one indicates a perfect ®t.
Comparisons of categorical data between participants and non-participants were carried out with Fisher-Freeman-Halton exact test, 32 and the statistical signi®cance was relaxed (that is, P`0.10) to increase the sensitivity to detect potential selection bias.
Results
Non-participants analysis
There were no statistically signi®cant differences in characteristics of participants and non-participants, evaluated from previously obtained information, 20, 21 concerning hypertension, diabetes mellitus, myocardial infarction, stroke and angina pectoris (not shown). As indicated by the relatively narrow CIs, these sample means seem to be suf®cient estimators of the unknown (true) population means (m i ). This data-set has previously been published, 2 but is included here to facilitate ease of reading. Table 2 shows the prevalence in the bottom 10th percentiles of T ( 13.13 nmolal) and IGF-I ( 128.80 mgal), in relation to the total study population and subgroups of the anthropometric measurements. The subgroups of BMI, WHR and D were de®ned by designating individuals within the top third stratum into one group and individuals within the lower two thirds strata into another group for each anthropometric measurement (that is, BMI!27.35 vs BMI`27.35, WHR!0.967 vs WHR`0.967 and D!24.0 vs D`24.0). The prevalence of low T was higher in the top third stratum of BMI (20.2%), WHR (17.5%) and D (17.1%), compared with the total study population (10.6%). In addition, the prevalence of low IGF-I was higher in the same BMI and WHR subgroups (14.9% and 17.5%, respectively), but not in the top third part of D (9.5%), when compared with the total study population (10.2%).
Descriptive statistics
Correlation analyses
In a ®rst analysis, low T and IGF-I values were excluded. Table 3 shows the connections between the anthropometric measurements, metabolic and hemodynamic variables in the total population of men and in the comparative population (that is, the bottom 10th percentiles of T and IGF-I excluded). BMI, WHR and D were positively signi®cantly correlated to fasting insulin and glucose, triglycerides, systolic and diastolic BP as well as HR, (except BMI P 0.106), and negatively to high density lipoprotein (HDL)-cholesterol, but not to total and low density lipoprotein (LDL)-cholesterol in both groups, irrespective of anthropometric variable.
To examine further whether the relationships between BMI, WHR and D on the one hand, and metabolic and hemodynamic variables on the other, were dependent on the endocrine status Table 2 The prevalence of the bottom 10th percentiles of testosterone (T 13.13 nmolal) and insulin-like growth factor I (IGF-I 128.80 mgal) in relation to the total study population and subgroups of the anthropometric measurements. Figures within parentheses are percentages of the total number of subjects in each group with exact 95% con®dence intervals for the proportions Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp (dexamethasone suppression, T and IGF-I), the following analyses were performed next. The associations with BMI are presented in Table 4 . In the subgroup with low T ( 13.13 nmolal), with blunted Dexamethasone suppression, BMI was signi®cantly positively related to fasting insulin and systolic BP (SBP), and negatively to LDL-cholesterol. In this subgroup with low T, but adequate Dexamethasone suppression, fasting insulin and SBP remained signi®cantly related to BMI, and diastolic BP (DBP) showed signi®cant correlations. In the subgroup with a low IGF-I ( 128.80 mgal) and blunted, as well as adequate, Dexamethasone suppression, BMI was signi®cantly positively associated to fasting insulin and glucose, triglycerides and BPs as well as HR, and negatively to HDL-cholesterol. In the comparative population, where low T and IGF-values had been removed, signi®cant correlations were found for the same variables, irrespective of the ef®ciency of dexamethasone suppression. A similar analysis now with the WHR and the metabolic and hemodynamic variables, in relation to the subgroups of T and IGF-I and the comparative population, are given in Table 5 . With blunted Dexamethasone suppression, in the subgroup with low T, WHR was signi®cantly positively related to fasting insulin, SBP and DBP (borderline, P 0.088), and negatively to HDL-cholesterol. With adequate Dexamethasone suppression, fasting insulin and glucose (borderline, P 0.080), as well as BPs, were signi®-cantly related to the WHR. In the subgroup with a low IGF-I and blunted Dexamethasone suppression, WHR was signi®cantly positively associated with fasting insulin, fasting glucose, triglycerides (borderline, P 0.090), BPs and HR, and negatively to HDLcholesterol (borderline, P 0.097). In addition, with adequate Dexamethasone suppression, WHR was signi®cantly positively associated to fasting insulin and glucose, triglycerides, BPs as well as HR, and negatively to HDL-cholesterol. In the comparative population with adequate or blunted dexamethasonesuppression, similar associations were found. Table 6 shows the same examinations in relation to D. With blunted Dexamethasone suppression, in the subgroup with low T, D was signi®cantly positively associated with fasting insulin, fasting glucose and SBP, and negatively with total and LDL-cholesterol. With adequate Dexamethasone suppression, fasting insulin, fasting glucose and SBP remained signi®-cantly related to D. In the subgroup with a low IGF-I, and blunted as well as with adequate Dexamethasone suppression, D was found to be signi®cantly positively related to fasting insulin, fasting glucose, triglycerides, BPs and HR, and negatively to HDLcholesterol. Similar signi®cant relationships were found in the comparative group, irrespective of dexamethasone suppression.
Path-analytic models
To examine hypothetical causal models between endocrine measurements, WHR, D, BMI, insulin and triglycerides we performed a path-analytic model. Table 7 illustrates such causal models in terms of path diagrams. In the models 1 ± 4 with T as the exogenous (independent) variable, the chi-square (w 2 ) statistic for the model, where T is associated with insulin and triglycerides via WHR (model 3), is 6.2 Â 10 76 (P 0.998), and the GFI is 1.0. The models 5 ± 8 with IGF-I as exogenous variable also showed a direct relationship with the WHR, interconnected with insulin and triglycerides (model 7, w 2 3.3, P 0.069, borderline), and the GFI and AGFI are 0.994 and 0.942, respectively. With a blunted Dex (models 9 ± 12), Dex and WHR were independently associated with insulin and triglycerides (model 10, w 2 1.1, P 0.579, GFI 0.997 and AGFI 0.987). Furthermore, with Dex as the exogenous variable, the chi-square (w 2 ) statistic for the model (no. 13), where T and WHR are the outcome variables, is 0.8 (P 0.850), and the GFI and AGFI are 0.998 and 0.995. In addition, the chi-square statistic for the model (no. 14), where IGF-I and WHR are the outcome variables, is 0.2 (P 0.978), and the GFI and Table 3 Spearman's rank-correlation coef®cient and P-values of the correlations between the anthropometric measurements, metabolic and hemodynamic variables in the total and comparative population (that is, total study population minus lowest decile of testosteronel T) and insulin-like growth factor I (IGF-I) Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp Table 4 Spearman's rank-correlation coef®cient and P-values of the correlations between body mass index (BMI), metabolic and hemodynamic variables in relation to the bottom 10th percentiles of testosterone (T) and insulin-like growth factor I (IGF-I) and the comparative population (CP) (that is, total study population minus lowest decile of T and IGF-I)
BMI
Weighted by blunted dexamethasone suppression HDL high-density lipoprotein; LDL low-density lipoprotein; SBP systolic blood pressure; DBP diastolic blood pressure. Table 5 Spearman's rank-correlation coef®cient and P-values of the correlations between waistahip circumference ratio (WHR), metabolic and hemodynamic variables in relation to the bottom 10th percentiles of testosterone (T) and insulin-like growth factor I (IGF-I) and the comparative population (CP) (that is, total study population minus lowest decile T and IGF-I)
WHR
Weighted by blunted dexamethasone suppression
Weighted by adequate dexamethasone suppression Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp AGFI are 0.994 and 0.998. Insulin was directly connected with triglycerides in all models. Pathways with a GFI!0.994 are summarised graphically in Figure 1 .
Other models showed a less satisfactory overall ®t. These included direct effects of T, IGF-I and Dex on metabolic variables or effects of the WHR on the endocrine variables.
A similar analysis was performed with BMI instead of WHR as shown in Table 8 Other models showed less satisfactory ®t such as direct effects of BMI on endocrine variables.
Similar analyses with the D showed the same relationships as with the WHR, except with a direct association between IGF-I and insulin (GFI 0.965 and AGFI 0.915) (not shown).
Discussion
Abdominal obesity has repeatedly been shown to be strongly associated with a number of endocrine, metabolic and hemodynamic abnormalities (for review, see Ref. 19 ). The metabolic and hemodynamic aberrations are established risk factors for cardiovascular disease (CVD), non-insulin dependent diabetes mellitus (NIDDM) and stroke, and abdominal obesity is an independent risk factor for these diseases in both men and women. 19 The relationship between measurements of obesity (BMI) and central localisation of body fat (WHR and D) on the one hand and the metabolic and circulatory risk factors on the other were also found in the men studied here (Table 3 ). The endocrine abnormalities in abdominal obesity in men described are perturbations of the regulation of the HPA axis, 1,2,11 , low T (in men), 3, 4 and a diminished growth hormone secretion, 6 as indicated by measurements of IGF-I. 7 These perturbations have been found to correlate with the risk Table 6 Spearman's rank-correlation coef®cient and P-values of the correlations between abdominal sagittal diameter (D), metabolic and hemodynamic variables in relation to the bottom 10th percentiles of testosterone (T) and insulin-like growth factor I (IGF-I) and the comparative population (CP) (that is, total study population minus lowest decile T and IGF-I)
D
Weighted by blunted dexamethasone suppression
Weighted by adequate dexamethasone suppression Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp factor pattern, particularly insulin resistance and visceral fat accumulation, the cardinal abnormalities of abdominal obesity. 9, 10 When substitution of T and GH is given, abdominal accumulation of body fat diminishes and the risk factor pro®le is clearly improved. 16, 17 Such observations suggest a putative causal relationship between the endocrine abnormalities and abdominal obesity and its associated risk factors. 18 With this background we found it of interest to analyse further the potential impact of the endocrine perturbations on the regulation of obesity, body fat distribution and metabolic and circulatory variables. For this purpose we selected different approaches. Men in a cohort from a randomly selected population were divided into subgroups, with different endocrine pro®les and associations to obesity and metabolic and circulatory factors analysed. Furthermore, statistical pathanalyses were performed.
The subgrouping was performed arbitrarily on statistical grounds, utilising percentiles. The borderlines Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp obtained, however, seem to be reasonable, based on previous information. The dividing point for BMI (!27.35) is close to that de®ning overweight-obesity, according to a current consensus. 33 The cutting line for the WHR (!0.967) is near the limit where risks for development of cardiovascular disease and NIDDM is rising. 34 D has not been evaluated prospectively. The upper borderlines for the tenth decile of T and IGF-I are 13.13 nmolal respectively 128.80 mgal in the men studied. Both these values seem to be tentatively reasonable limits for low T and IGF-I, according to clinical practice. Lower T values than these were found in men with abdominal obesity (highest tertile of BMI, WHR or D) in about 17 ± 20%, and about 6 ± 7% with men with lower values of BMI, WHR or D (Table 2) . Similarly, IGF-I values were below the selected borderline in 10 ± 18%, compared with 7 ± 10% of men without indications of abdominal obesity, according to the de®nitions utilised. These estimations indicate that low T and IGF-I values are occurring frequently in men with abdominal obesity, as previously reported.
3,4,6,8 It may be expected that GFI goodness-of-®t index; AGFI goodness-of-®t index adjusted for degrees of freedom
Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp this becomes more prevalent in older age groups than studied in this work. Since the dexamethasone suppression test was developed recently, 11 normal borderlines are not available. Therefore, the impact by this factor was evaluated by weighting.
With these considerations, the prevalence of abdominal obesity may be considered to be 33% in this population of men. Utilising the prevalence of low T and IGF-I values described above, about 17 ± 20% and 10 ± 18%, respectively, of these men had low values. Transferred to the total population, Swedish men at this age (51 y) show a prevalence of about 5 ± 6% of abdominal obesity combined with low T values. The corresponding ®gure for IGF-I would be about 3 ± 6%. It is then apparent that men with low T and IGF-I values constitute a signi®cant fraction of the total population having abdominal obesity, with its associated risk factors.
In order to study the impact of the endocrine perturbations on obesity and metabolic and circulatory factors, the men with the lowest T or IGF-I were ®rst removed. This did not result in any certain changes in the relationships studied in the total population ( Table  3) . Next the relationships between obesity factors (BMI, WHR and D) and metabolic and circulatory variables were analysed in isolated subgroups with low T or IGF-I values, where a statistical weighting of the status of the HPA axis was introduced, as measured by Dexamethasone inhibition of cortisol secretion. The results then showed remaining associations in these subgroups on several points, with the exception of total and LDL cholesterol values (Tables 4±6), including the subgroups without apparent HPA-axis involvement. There were, however, some noticeable differences in the subgroups of low T and IGF-I, where the former showed relationships between obesity factors only in insulin and BPs, while the low IGF-I group showed associations with all measured variables except total and LDL cholesterol. These observations suggest that the impact by T and IGF-I might be different.
The importance of HPA-axis involvement was evaluated in the groups where the lowest T and IGF-I values have been removed (`comparative group') with blunted dexamethasone inhibition. Here associations with obesity factors were uniformly seen, again with the exception of total and LDL cholesterol values. In the comparative group with adequate dexamethasone inhibition, the impact of obesity factors without major endocrine perturbations can be evaluated. Strong, consistent relationships were remaining. It had been of interest to analyse subgroups with only endocrine perturbations, but without in¯uence of obesity factors. Such subgroups became, however, too small to allow meaningful calculations.
The ®ndings presented indicate several, potentially interesting possibilities for the complex interactions between abdominal obesity and endocrine perturbations on the one hand and the metabolic and hemodynamic abnormalities on the other. The arbitrary, statistical division lines utilised to obtain groups with different impact of abdominal obesity and abnormal endocrine factors suggest that abdominal obesity, HPA axis perturbations, as well as low T and IGF-I concentrations, all have an impact on the factors related to complications, either in combinations, or each alone. This in turn suggests subgrouping of the syndrome of abdominal obesity with different backgrounds.
With these results known we found it interesting to try to analyse putative primary factors in a potential chain of events leading to the main symptoms. This was performed statistically by path analyses. For these analyses, the following variables were selected. Abdominal fat distribution usually shows stronger relationships with endocrine, metabolic and hemodynamic perturbations in comparisons with peripheral obesity, as well as with the total population of obesity. 9, 35 Therefore, the WHR and D were selected for detailed path analyses. Furthermore, BMI was included because this measurement provides an estimation of obesity, irrespective of the localisation of excess body fat. This factor is clearly dependent on the regulation of energy balance, while the localisation of body fat, as measured by the WHR and D, is probably regulated by other factors, where endocrine perturbations such as those described in this work have been implicated. 18 Fasting insulin was selected to represent insulin resistance, based on the potential importance of insulin resistance for the generation of other metabolic and hemodynamic perturbations, 36 represented here for simplicity, by triglyceride concentrations only. In addition, insulin resistance is probably the most prevalent perturbation in abdominal obesity. 19 Total and LDL cholesterol show less strong relationships to abdominal obesity than insulin and triglycerides, 9 as also seen in the results presented here, and were therefore not included.
A blunted dexamethasone suppression of cortisol secretion is indicating a de®cient feed-back control of the HPA axis, and was therefore used as a marker of HPA axis status. Decreased dexamethasone suppression has previously been found in abdominal obesity. 2, 11 In the path analyses putative primary pathogenetic factors were selected to be the endocrine variables and the WHR, D or BMI and models were tested to estimate whether these variables were interacting with each other and with the metabolic variables insulin and triglycerides. With the WHR (Figure 1 ), triglyceride concentration was consistently dependent on insulin in all models. Insulin concentrations in turn were directly dependent on the WHR as well as the dexamethasone suppression. T and IGF-I were found to interact with metabolism via the WHR. T and IGF-I in turn were dependent on the dexamethasone test, suggesting that HPA axis perturbations inhibit T and growth hormone secretions. Elevated WHR did not seem to determine the endocrine abnormalities In summary, this analysis suggests that the endocrine perturbations are primary factors in a Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp pathogenetic chain of events. The model visualised in Figure 1 seems to best satisfy the path analyses ®ndings.
When the BMI was included (Figure 2 ) partly different results were obtained. Again triglycerides were consistently dependent on insulin. Insulin in turn was directly dependent on BMI and DEX, and in contrast to the WHR and D analyses, also on T and IGF-I. DEX in turn seemed to regulate not only IGF-I and T, but also BMI and insulin. Again the endocrine perturbations were ®rst in a putative chain of pathogenetic events, regulating not only BMI, but also major metabolic perturbations.
We are aware of the uncertainties of statistical path analyses, which can only be useful as an analytic approach for testing causal hypotheses. 30, 31 The results obtained seem, however, possible to interpret in reasonably credible mechanistic terms. A blunted dexamethasone suppression of cortisol secretion is a sign of a de®cient control of the HPA axis activity. 13, 14 Evidence for perturbations of HPA axis regulation in abdominal obesity, has now been repeatedly reported. 1, 11, 37, 38 According to the pathway suggested by the analyses, it seems that a blunted dexamethasone test is affecting both the T and IGF-I concentrations. This is in accordance with observations that both the pituitary-gonadal, and the growth hormone axes, are inhibited by an elevated HPA axis activity. 13, 14 T and IGF-I values were followed by an elevated WHR, D and BMI in the path-analytic models. Low growth hormone and T secretions have previously been reported to be statistically associated with abdominal obesity and appropriate substitutions are resulting in diminution of visceral fat masses. 16, 17 These mechanisms at the cellular level have been at least partly clari®ed. 18 The results suggest that there might be a causal connection between low T and GH secretions and abdominal obesity.
Increased secretion of cortisol is known to lead to accumulation of total and visceral fat, as seen in Cushing's syndrome, is normalised with effective treatment, 39 and the mechanisms are at least partly known. 18 A blunted dexamethasone test was, however, not directly related to the WHR, but seemed to be active via inhibition of IGF-I and T secretion, which then might be more powerful in the regulatory events leading to visceral fat accumulation.
Although a direct pathway between HPA axis perturbations, as indicated by the DEX, was missing for the WHR, this was found for the BMI. These ®ndings suggest different regulatory mechanisms for the distribution of body fat (WHR and D) and the accumulation of body fat mass (BMI). Leptin concentrations were determined in these subjects retrospectively and were elevated in parallel with BMI (not shown). Since normal leptin action would be expected to prevent obesity, by inducing satiety, 40 the combination of elevated BMI and leptin suggests a leptin resistance, described previously. 41 Recently, cortisol has been shown to prevent normal leptin action in rats, probably by interactions at the receptor level, resulting in overeating and obesity. The results of the path-analyses described here might mean that a similar pathway is also active in humans. If this turns out to be the case, then the HPA-axis might be regulating fat distribution mainly via interactions with other endocrine systems, while total body fat is dependent on direct actions of the HPA axis on mechanisms leading to obesity.
Mechanisms for insulin regulation of triglyceride metabolism have been described. 36 Insulin was dependent on input from the WHR and from the dexamethasone test, and therefore presumably on cortisol secretion. Insulin resistance and hyperinsulinaemia are well established consequences of elevated cortisol secretion, and effects of low T and IGF-I have also been described. 17, 19 Visceral adipose tissue is equipped with a highly sensitive lipolytic machinery, 42 mobilising free fatty acids (FFA). FFA most likely induce insulin resistance in both muscles and liver. It might therefore be possible that the connection between the WHR and insulin, is a consequence of enlarged visceral fat depots producing an excess of FFA into the portal, as well as systemic, circulation ± the latter by hepatic over¯ow (for review, see Ref. 43 ). We have previously suggested that portal FFA might be major factors in the generation of the metabolic abnormalities found in visceral obesity. 44 This suggestion has recently found considerable support. Hepatic triglyceride concentration is related to visceral fat mass and insulin resistance. Since hepatic triglycerides are a result of portal FFA¯ow, such ®ndings suggest that an elevated concentration of FFA in the portal vein, produced by an enlarged visceral fat mass, is indeed occurring. 45, 46 Hepatic triglyceride production and secretion are also dependent on FFA as substrate (for review, see Ref. 44) .
One note-worthy observation in this analysis is that obesity and abdominal fat distribution seem to be secondary to the endocrine abnormalities, and not the other way around. Although the path analyses are indicative of possible pathways of interactions between various factors, such analyses only indicate the strongest statistical connections, which do not exclude other alternatives of less impact. Interactions other than those selected by ®ndings of best ®ts in the statistical procedure may therefore well be present. Taken together, it seems possible to construct a reasonable¯ow sheet of events as follows. HPA axis perturbations are interfering with secretion of growth hormone and T, which is followed by visceral fat accumulation as well as total body fat, the latter reinforced by direct actions of the HPA-axis on total body fat. This in turn, combined with the HPA axis perturbation and a low T and GH, seems to be mainly responsible for the metabolic perturbations, including insulin resistance. Such an interpretation seems to be in harmony not only with the results of path analyses, presented in this work, but also with results previously reported in mechanistic studies.
Hormones, metabolism and hemodynamics in abdominal obesity R Rosmond and P Bjo Èrntorp A further interpretation of the results of the pathanalyses is that the metabolic abnormalities which are strongly statistically associated with abdominal obesity might be induced by interference at different levels of the putative chain of events (see Figure 1 and Figure 2 ). Obesity (Figure 2 ), localised to the abdominal regions (Figure 1 ) may by itself be followed by metabolic perturbations without major reinforcements of the endocrine factors, which is in accordance with the results of Tables 4±6, where the subgroup without major endocrine abnormalities still shows strong relationships to metabolic and circulatory variables. Going one step proximally in the putative pathogenetic chain of events, low T and IGF-I might be pathogenetic events which are active mainly via directing excess body fat to central depots. Perturbations of the HPA axis exert major effects either directly on total body fat and insulin resistance or indirectly via low T and IGF-I.
These interpretations are compatible with the results of the analyses of the endocrine subgrouping. It may therefore be warranted to suggest that the risk factor cluster of abdominal obesity with its associated metabolic and circulatory perturbations, also called the Metabolic Syndrome, Syndrome X or insulin resistance syndrome, 18, 36 are dependent on different pathogenetic pathways. Such subgroups might consist of primary perturbations of the HPA axis often, but perhaps not always followed by other endocrine abnormalities. Other subgroups might consist of primary de®ciencies of sex steroid and GHs. Abdominal obesity may also be considered to develop without endocrine abnormalities, by factors not yet elucidated. There are most likely several genetic components involved, where perhaps primary genetic defects in visceral adipose tissue may be predominant in leading to visceral distribution of body fat. Subgrouping along the principles outlined above may lead to a better understanding of underlying pathogenetic mechanisms involved and thereby helps to develop adequate, causative prevention and treatment.
